Trial Profile
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors AbbVie
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2017 Planned End Date changed from 31 Oct 2017 to 27 Nov 2017.
- 11 Oct 2017 Planned primary completion date changed from 31 Oct 2017 to 27 Nov 2017.